Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).

被引：0
|
作者：
Montgomery, Robert B.
Eisenberger, Mario A.
Rettig, Matthew
Chu, Franklin
Pili, Roberto
Stephenson, Joe
Vogelzang, Nicholas J.
Morrison, Jodie
Taplin, Mary-Ellen
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Johns Hopkins Univ, James Buchanan Brady Urol Inst, Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[4] San Bernadino Urol Associates, San Bernardino, CA USA
[5] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[6] Canc Ctr Carolinas, Greenville, SC USA
[7] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[8] US Oncol Res, Las Vegas, NV USA
[9] Tokai Pharmaceut, Boston, MA USA
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4665
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy naive patients with castration resistant prostate cancer (CRPC)
    Taplin, Mary-Ellen
    Chu, Franklin
    Morrison, Jodie P.
    Pili, Roberto
    Rettig, Matthew B.
    Stephenson, Joe
    Vogelzang, Nicholas J.
    Montgomery, R. Bruce
    CANCER RESEARCH, 2012, 72
  • [2] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    Attard, Gerhardt
    Reid, Alison H. M.
    Yap, Timothy A.
    Raynaud, Florence
    Dowsett, Mitch
    Settatree, Sarah
    Barrett, Mary
    Parker, Christopher
    Martins, Vanessa
    Folkerd, Elizabeth
    Clark, Jeremy
    Cooper, Colin S.
    Kaye, Stan B.
    Dearnaley, David
    Lee, Gloria
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4563 - 4571
  • [3] Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
    Eisenberger, Mario A.
    EUROPEAN UROLOGY, 2009, 55 (01) : 248 - 248
  • [4] Re: Phase I Clinical Trial of a Selective inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
    Schalken, Jack A.
    EUROPEAN UROLOGY, 2008, 54 (06) : 1438 - 1439
  • [5] Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven Comment
    Walsh, Patrick C.
    JOURNAL OF UROLOGY, 2009, 181 (03): : 1124 - 1124
  • [6] Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
    Ryan, Charles J.
    Smith, Matthew R.
    Fong, Lawrence
    Rosenberg, Jonathan E.
    Kantoff, Philip
    Raynaud, Florence
    Martins, Vanessa
    Lee, Gloria
    Kheoh, Thian
    Kim, Jennifer
    Molina, Arturo
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1481 - 1488
  • [7] Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
    Gupta, Shilpa
    Nordquist, Luke T.
    Fleming, Mark T.
    Berry, William R.
    Zhang, Jingsong
    Ervin, Sharon L.
    Eisner, Joel R.
    Baskin-Bey, Edwina S.
    Shore, Neal D.
    CLINICAL CANCER RESEARCH, 2018, 24 (21) : 5225 - 5232
  • [8] The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models.
    Moore, William R.
    Maity, Sankar N.
    Eisner, Joel Robert
    Garvey, Edward P.
    Hoekstra, William J.
    Titus, Mark Anton
    Logothetis, Christopher
    Araujo, John C.
    Efstathiou, Eleni
    Schotzinger, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [9] Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience
    Reid, A.
    Attard, G.
    Oommen, N. Babu
    Olmos, D.
    Fong, P.
    Molife, R.
    Dowsett, M.
    Lee, G.
    Molina, A.
    De-Bono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 12 - 12
  • [10] Re: Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms that Castration-Resistant Prostrate Cancer Commonly Remains Hormone Driven
    Vogelzang, Nicholas J.
    EUROPEAN UROLOGY, 2009, 56 (01) : 220 - 220
12345